her2 expression should be routinely evaluated in dcis to avoid under or overtreatment | oncoscience
Published 1 year ago • 459 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
59:44
new perspectives on the full spectrum of her2 expression in breast cancer
-
11:31
prognostic and predictive value of her2 expression in ductal carcinoma in situ
-
0:34
unanswered questions in dcis progression
-
17:37
dcis breast cancer: learn what you need to know
-
21:53
dcis recurrence and radiation
-
26:25
treatment decision making for dcis - dr. monica morrow
-
6:51
recurrence risk could be predicted by a multigene test in ductal carcinoma breast cancer
-
4:31
is dcis dangerous or over-treated? how can you manage the risks?
-
1:14
dr. kuerer on the overtreatment of dcis
-
2:07:00
avoiding over and under treatment in "ductal carcinoma in situ"
-
5:52
treatment options for dcis or non-invasive breast cancer (stage 0)
-
10:42
deescalating dcis experts discuss new data from sabcs
-
52:08
emerging strategies in breast cancer care before, during and after surgery
-
4:03
what treatment should women with dcis think about?
-
0:34
understanding invasive and non-invasive breast cancer: what you need to know
-
9:05
ductal carcinoma in situ (dcis): mayo clinic radio
-
7:08
overtreatment of stage 0 breast cancer dcis
-
3:29
what is new in the treatment of dcis breast cancer?
-
0:39
what is her2 in #breastcancer?